Loading…
Iovance Biotherapeutics, Inc. is projected to rise to $5.47 by 2027, a +25% move from its current price of $4.37. IOVA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.18 | $4.37 | $4.57 | +0.07% |
| May 30 | $4.11 | $4.38 | $4.66 | +0.14% |
| May 31 | $4.06 | $4.38 | $4.73 | +0.22% |
| Jun 1 | $4.01 | $4.38 | $4.79 | +0.29% |
| Jun 2 | $3.97 | $4.39 | $4.84 | +0.36% |
| Jun 3 | $3.94 | $4.39 | $4.89 | +0.43% |
| Jun 4 | $3.91 | $4.39 | $4.93 | +0.50% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.91 | $4.39 | $4.93 | +0.50% |
| Week 2 | $3.74 | $4.41 | $5.20 | +1.01% |
| Week 3 | $3.63 | $4.44 | $5.43 | +1.52% |
| Week 4 | $3.53 | $4.46 | $5.63 | +2.03% |
| Week 5 | $3.45 | $4.48 | $5.81 | +2.54% |
| Week 6 | $3.39 | $4.50 | $5.99 | +3.05% |
| Week 7 | $3.33 | $4.53 | $6.16 | +3.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Iovance Biotherapeutics, Inc. (IOVA) is a healthcare company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma; LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company collaborates and licenses with the National Institutes of Health, the National Cancer Institute, Cellectis S.A., Novartis Pharma AG, and Boehringer Ingelheim Biopharmaceuticals GmbH. It was formerly known as Lion Biotechnologies, Inc.
and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA is a biotechnology company operating in the Healthcare sector, focused on cell therapies using autologous TILs for metastatic melanoma and other solid tumors. The stock trades at $4.11 with a market cap of $1.84B and is ranked 2058. The near-term picture aligns with a bullish technical setup, while the longer-term view is defined by a year-by-year forecast showing meaningful upside in several periods.
A major floor 46.0% below — a decisive break under it would weaken the trend.
The nearest floor, 24.3% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 23.8% above — clearing it would confirm fresh momentum.
Key IOVA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IOVA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.96 | Buy | $4.03 | Buy |
| MA 10 | $3.73 | Buy | $3.86 | Buy |
| MA 20 | $3.69 | Buy | $3.75 | Buy |
| MA 50 | $3.64 | Buy | $3.63 | Buy |
| MA 100 | $3.37 | Buy | $3.41 | Buy |
| MA 200 | $2.84 | Buy | $3.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.08 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 189.05 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.08 | Buy |
| ROC (12) | 20.72 | Buy |
| Bollinger %B (20,2) | 1.09 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | 0.29 | Buy |
| Ultimate (7,14,28) | 77.75 | Sell |
| Momentum (10) | 0.81 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 4.28 | Buy |
| ADX (14) | 12.87 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 60. The 50-day moving average is $3.63 and the 200-day moving average is $2.82, indicating an upward trajectory. Support is identified at $3.31 and resistance at $4.11, framing a trading range that sits near the current price.
The 30-day range spans from $3.06 to $5.52, illustrating a broad near-term volatility band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.22 | $4.37 | $6.05 | 0% | Neutral | |
| $4.08 | $5.47 | $7.89 | +25% | Bullish | |
| $3.87 | $5.44 | $8.28 | +25% | Bullish | |
| $4.39 | $6.42 | $10.18 | +47% | Bullish | |
| $5.65 | $8.57 | $14.06 | +96% | Bullish | |
| $6.97 | $10.93 | $18.47 | +150% | Bullish | |
| $7.83 | $12.67 | $21.99 | +190% | Bullish | |
| $7.49 | $12.49 | $22.20 | +186% | Bullish | |
| $7.47 | $12.84 | $23.33 | +194% | Bullish | |
| $8.07 | $14.25 | $26.43 | +226% | Bullish | |
| $12.67 | $25.58 | $51.61 | +485% | Bullish | |
| $28.00 | $62.22 | $141.39 | +13.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.22 | $4.37 | $5.21 | +0.00% |
| June 2026 | $3.94 | $4.69 | $5.76 | +7.26% |
| July 2026 | $3.87 | $4.67 | $5.85 | -0.47% |
| August 2026 | $3.74 | $4.56 | $5.81 | -2.28% |
| September 2026 | $3.81 | $4.68 | $6.05 | +2.75% |
| October 2026 | $3.81 | $4.73 | $6.18 | +0.90% |
| November 2026 | $3.63 | $4.53 | $5.99 | -4.06% |
| December 2026 | $3.61 | $4.54 | $6.05 | +0.15% |
Click any year to see its month-by-month IOVA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IOVA price prediction for 2026 points to an average of $4.37 (low $2.22, high $6.05) — a potential gain of 0% on today's $4.37. Price action looks broadly range-bound.
In 2027, IOVA is projected to trade between $4.08 and $7.89, averaging $5.47 — a potential gain of +25% from today's $4.37. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Iovance Biotherapeutics, Inc.'s 2028 outlook centres on $5.44, within a $3.87 to $8.28 range. That is 0% versus the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, IOVA could reach as high as $10.18, with a base case around $6.42 and support toward $4.39 — roughly +47% from $4.37. Buyers look set to stay in control over this stretch.
Expect IOVA to range from $5.65 to $14.06 through 2030. The $8.57 average target implies a +96% move from current prices. That is up +33% on the projected 2029 average. Momentum favours further upside here.
The IOVA price prediction for 2031 points to an average of $10.93 (low $6.97, high $18.47) — a potential gain of +150% on today's $4.37. Buyers look set to stay in control over this stretch.
In 2032, IOVA is projected to trade between $7.83 and $21.99, averaging $12.67 — a potential gain of +190% from today's $4.37. That is up +16% on the projected 2031 average. Momentum favours further upside here.
Iovance Biotherapeutics, Inc.'s 2033 outlook centres on $12.49, within a $7.49 to $22.20 range. That is -1% versus the projected 2032 average. That marks a +186% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, IOVA could reach as high as $23.33, with a base case around $12.84 and support toward $7.47 — roughly +194% from $4.37. Momentum favours further upside here.
Expect IOVA to range from $8.07 to $26.43 through 2035. The $14.25 average target implies a +226% move from current prices. That is up +11% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The IOVA price prediction for 2040 points to an average of $25.58 (low $12.67, high $51.61) — a potential gain of +485% on today's $4.37. Momentum favours further upside here.
In 2050, IOVA is projected to trade between $28.00 and $141.39, averaging $62.22 — a potential gain of +13.2x from today's $4.37. That is up +143% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in IOVA today (≈ 228.832952 IOVA) could be worth
$14,237.86
+$13,237.86 (+1324%) by 2050 · US Dollar
Based on the average projected IOVA price of $62.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IOVAwould be worth at today's price.
$1,000 invested in IOVA on May 27, 2025 (≈ 578.034676 IOVA) would be worth
$2,526.01
+$1,526.01 (+152.6%) today · 2.53× · US Dollar
Based on a IOVA entry price of $1.73 vs. today's $4.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.54 | $1,234.46 | +23.4% |
| 1 month ago | $3.43 | $1,274.05 | +27.4% |
| 3 months ago | $3.79 | $1,153.03 | +15.3% |
| 6 months ago | $2.47 | $1,769.23 | +76.9% |
| 1 year ago | $1.73 | $2,526.01 | +152.6% |
| All time (5.0y) ago | $18.27 | $239.19 | -76.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IOVA forecast.
Our base-case forecast reaches $8.70 around 2031.
Implied market cap at $8.70: $3.88B
The multi-year forecast presents a clear upward trajectory with a progression of higher averages and sizable ROI in later years. In 2026, the average price is $4.11 with a min of $2.22 and a max of $5.68, and a 0% ROI. By 2027 the average rises to $4.99 (min $3.71, max $7.23) with a 21.4% ROI, followed by 2028 at $4.77 (min $3.38, max $7.29) with a 16.1% ROI.
In 2029 the average is $5.56 (min $3.79, max $8.86) and ROI is 35.4%. Looking further, 2030 shows $7.23 as the average (min $4.74, max $11.92) with a 75.9% ROI, and 2031–2032 continue bullish momentum (2031 avg $9.11, max $15.47; 2032 avg $10.61, max $18.52). The forecast extends to 2033–2035 with continued bullish sentiment and double-digit to triple-digit ROI figures, including 2035 avg $11.52 and ROI 180.3%.
In 2040 the average is $19.66 with a 378.3% ROI, and by 2050 the average reaches $46.77 with a max of $107.06 and a 1,037.8% ROI. These figures reflect bullish expectations over the long term, but they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $7.23 with a min of $4.74 and a max of $11.92, and a 75.9% ROI. The sentiment is BULLISH.
The forecast includes years with bullish sentiment and positive ROI, such as 2030 (75.9%), 2050 (1,037.8%), and multiple years into the 2020s and 2030s. It also shows neutral years like 2026 (0% ROI). These figures are estimates and not guarantees.
The 2027 forecast lists an average of $4.99 with a max of $7.23, indicating a potential move above $5.00 on the high end.
The current price is $4.11 and the market cap is $1.84B.
The 30-day range is $3.06 to $5.52.
Iovance Biotherapeutics, Inc. Community Discussion
0Share your Iovance Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.